213 related articles for article (PubMed ID: 33821775)
1. Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
Yamamoto K; Oka K; Son R; Honda H; Sakae H; Hasegawa K; Horiguchi S; Kato H; Yamasaki O; Otsuka F
Mod Rheumatol Case Rep; 2021 Jul; 5(2):425-430. PubMed ID: 33821775
[TBL] [Abstract][Full Text] [Related]
2. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
5. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Nivolumab-Induced Autoimmune Pancreatitis.
Goyal P; Moyers JT; Elgohary BG; Hammami MB
J Immunother Precis Oncol; 2021 Nov; 4(4):208-211. PubMed ID: 35665025
[TBL] [Abstract][Full Text] [Related]
7. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab.
Starling CT; Messer AA; Kleiman A; McQuade JL; Glitza IC; Torres-Cabala CA; Heberton M
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670686
[TBL] [Abstract][Full Text] [Related]
8. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
9. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
10. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
11. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
12. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
14. Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy.
Montes G; Duval F; Eldani C; Amico S; Gérard E; Dutriaux C; Herran C; Poullenot F; Sole G; Carla L; Guerin C; Célerier P; Prey S
J Immunother; 2021 Nov-Dec 01; 44(9):348-350. PubMed ID: 34166302
[TBL] [Abstract][Full Text] [Related]
15. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma.
Mullally WJ; Cooke FJ; Crosbie IM; Kumar S; Abernethy VE; Jordan EJ; O'Connor M; Horgan AM; Landers R; Naidoo J; Calvert PM
Front Immunol; 2022; 13():871217. PubMed ID: 35514990
[TBL] [Abstract][Full Text] [Related]
17. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
19. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy.
Pacholczak-Madej R; Grela-Wojewoda A; Lompart J; Żuchowska-Vogelgesang B; Ziobro M
Prague Med Rep; 2022; 123(1):35-42. PubMed ID: 35248163
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
